Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank - Yahoo Finance
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2024 Earnings Call Transcript - Insider Monkey
Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2024 Earnings Call Transcript - Insider Monkey
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth - MSN
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y - MSN
Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects - TipRanks
SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth - TipRanks
(SAGE) Technical Data - Stock Traders Daily
SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges - TipRanks
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
next ›
last »
×